This result suggests that the inhibition of estrogen receptor signaling and E2F6 (by using DNMT or EZH2 inhibitor) may be able to suppress cancer stemness and restore anti-tumor immune response in ovarian cancer. This evidence concerns the gene EZH2 and ovarian carcinoma.